Brand's research revealed that many practicing oncologists still lacked a strong, consistent understanding of HER2 testing's role in biliary tract cancer (BTC) and how it impacts sequencing first-line vs next-step therapy.
Only 34% chose the correct "next best step" now the #1 content focus

Accuracy rose 67% to 73% once mechanism-of-action content launched.

On-list oncologists score 73% vs 45% for broader traffic—ideal mentors for next phase.

245 oncologists entered the case study; 187 completed (≈76% finish) and 179 answers for granular gap mapping.

MDLinx combines a curated, NPI-verified HCP audience with adaptive micro-learning to deliver brand-specific education and capture rich behavioral signals—opens, dwell time, quiz accuracy, and ICS interaction data.


Data and experience—
deeply unified—so every tactic aligns with your brand's highest-value objectives.

Contact us for a quick walkthrough of the MDLinx engagement engine.